Table 1.

Baseline Characteristics of Recipients with Mixed Hematopoietic Chimerism

Hematopoietic Cell Transplantation (HCT)						Interval between HCT + OLT (months)	Orthotopic Lung Transplantation (OLT)
Recipient	Age at HCT (months)	TBI dose^* (cGy)	Source of HSC		Post-HCT IS^**		Donor Chimerism
Recipient	Age at HCT (months)	TBI dose^* (cGy)	Marrow Cells/Kg (×10⁸)	G-PBMC Cells/Kg (×10⁸)	Post-HCT IS^**		Age at OLT (months)	Before OLT (%)	6 Wk Post- OLT (%)
G190	9	200	4.0	0	CSP/MMF	7	16	L=76.2 G=81.3	L=74.7 G=78.5
G005	22	S5/200	4.0	10.5	CSP/MMF	13	35	L=32.0 G=57.4	L=53.2 G=44.7
E875	45	200	0	2.8	None	5	50	L=74.6 G=100	L=80.2 G=100
G246	15	200	6.7	8.7	CSP/MMF	11	26	L=60.8 G=91.1	L=37.4 G=68.3
G183	15	200	4.7	0	CSP/MMF	21	36	L=37.1 G=71.6	L=60.3 G=92.7

BM = bone marrow; CSP = cyclosporine; G-PBMC = granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood mononuclear cells; HCT = hematopoietic cell transplantation; HSC = hematopoietic stem cell; IS = immunosuppression; MMF = mycophenolate mofetil; OLT = orthotopic lung transplantation; S5 = CD44-specific monoclonal antibody; TBI = total body irradiation. For donor chimerism in peripheral blood: L= CD3+ lymphocytes, G= granulocytes

TBI was delivered at doses of 2 Gy from a high energy linear accelerator (Varian CLINAC 4, Palo Alto, CA) at a rate of 7 cGy/min.

^**

For immunosuppression, oral cyclosporine (15 mg/kg b.i.d.) was administered for 35 days and mycophenolate mofetil (10 mg b.i.d., s.c.) was administered for 28 days after HCT.